Lancashire Objective Volume Evaluation of Leg Oedema in Heart Failure

Heart Failure Clinical Trial

— LOVE-HF  

Official title:

Lancashire Objective Volume Evaluation of Leg Oedema in Heart Failure (LOVE-HF) Double Blinded Pilot Randomised Controlled Cross-over Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04787380
• Other study ID #: BTH01.1
• Status: Completed
• Phase: N/A
• Start date: March 5, 2021
• Est. completion date: September 30, 2021

Study information

• Verified date: March 2022
• Source: Heartfelt Technologies
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with heart failure (HF) who recently received treatment with IV diuretics for worsening congestion or outpatients with HF and peripheral oedema treated with at least 80 mg furosemide (or equivalent)/day will be recruited for the LOVE-HF trial at Blackpool Victoria Hospital.

Eligible participants will be randomized to use the Heartfelt Device alongside standard care (weighing + symptom reporting), or standard care alone. Participants and clinicians will be blinded (double blind) as to which arm participants are in, and after 30 days, participants will be crossed over to the other arm. This can be done without disrupting patients as the Heartfelt device can be switched remotely from a 'technical checks only' mode to a 'full data analysis' mode and vice versa. The investigators aim to recruit 30 participants for the pilot study. The study will also run in parallel with its sister pilot trial, LOVE-HF-2.

Through this study, we are testing the capability to get the answers from patients, healthcare systems, and devices, in order to inform future clinical trial design.

Description:

Heart Failure is the final common pathway of most forms of cardiovascular disease. In the United Kingdom (UK), it affects around 900 000 people, causes or complicates around 5% of adult emergency hospital admissions and consumes up to 2% of total National Health Service (NHS) expenditure. An important part of discharge planning includes measures such as early follow up in order to prevent readmissions. The hallmark of heart failure is fluid retention and between 2009 and 2016, 43% to 50% of hospital admissions were associated with peripheral oedema. Therefore, early recognition of this and treatment of the congestion may prevent hospital admissions. In clinical trials, management strategies have included patient education, telemedicine and remote monitoring. The main non-invasive method for detecting fluid retention has been the use of weight as a surrogate marker.

The Heartfelt device is an invention that uses a system of cameras in a compact device in order to generate 3 dimensional images of the feet and lower legs. The volumes can then be calculated and thus, changes in amount of peripheral oedema can be estimated. In a clinical trial (NCT02993601) performed by the Heart Failure team at the Royal Brompton Hospital, there was good correlation between measurements made by Heartfelt and a water displacement method. The resolution was as good as 20mls.

By positioning the Heartfelt device in the bedroom, automatic measurements can be made whenever the subject gets in and out of bed. Images are only taken of the specified subject. Data is censored so that the part of the body which is 50cm above the floor is not stored. Encrypted, anonymised data is transmitted over the internet to the company's secure servers. Personal identifiable data (participant name, address, age…) is stored on an encrypted hard drive, along with linkage information (device serial numbers) to associate the participant identifiable data with the data captured in the home. Therefore, data collection is not only secure but entirely passive, which is a major advantage compared with previous non-invasive methods and it is applicable to a very wide range of compliant and non-compliant patients.

Our hypothesis is that the Heartfelt device can directly detect the increase in peripheral oedema associated with heart failure decompensation and that, on average, the number of days with missing data collected by the Heartfelt device will be lower than that of the weighing scales.

Blackpool Victoria Hospital provides acute heart failure service both for in-patients and out-patients, including capacity to administer parenteral furosemide in hospital cardiac day case unit, community or home settings.

Participants with chronic heart failure will be monitored in their home using the Heartfelt device (experimental arm only). Participants in both arms will also receive standard care. "Standard care" means that participants will be encouraged to report symptoms and weigh themselves on a regular basis (as per the recommendation of their doctor or heart failure nurse) reporting them without delay. This will be done in line with current advice given to heart failure patients locally, which is that patients should record their weight in a diary and seek urgent medical attention if their weight goes up by at least 2 to 3 pounds in 24 hours, or 5 pounds or more in one week, or if they notice an increase in leg swelling and/or an increase in breathlessness.

Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per the usual advice given to patients, thus taking part in the study should not change their behaviour. Temporal changes in weight and volume will be compared. Research questionnaires will also be used to estimate the quality of life, mental wellbeing and hope status of participants and collect feedback on the device and study design.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: September 30, 2021
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with HF who recently (<6 months) received treatment with IV diuretics for worsening congestion or outpatients with HF and peripheral oedema (any degree) treated with at least 80 mg furosemide (or equivalent)/day.

• Patients with HF =18 years.

• Note that the research team will try to include as many patients as possible in the month following discharge, however we will not exclude consideration of a small proportion of patients within 6 months of decompensation. This has the extra advantage of demonstrating value of the device beyond 1-2 months of decompensation.

Exclusion Criteria:

1. Inability to provide informed consent *

2. Participant has bandages to lower limbs everyday

3. Participant has an amputation of the foot

4. Participant is a regular wheelchair user

5. Participant is of no fixed abode

6. Participant has potentially reversible cause of decompensated heart failure and is awaiting urgent intervention (revascularisation/ valvular heart disease), which means the patient cannot be discharged for home-based care.

7. Participant is taking part in a conflicting evaluation/study that could confound the results of this evaluation by and/or impact clinical interventions and participant outcomes.

8. Participant must not be pregnant, and is taking relevant birth control if of child-bearing potential*

• Note that a participant not able to comply with weighing is NOT an exclusion criteria as the Heartfelt Device should provide data for these participants despite their lack of ability to adhere to the usual monitoring protocol, and this is seen as one of the long term benefits that the device can provide.

• Note that the exclusion criteria (a) has been added as participants would need to be able to give individual responses to questionnaires, communicate directly with the Heartfelt team, etc.

• Note that the exclusion criteria (h) has been requested by the insurance for clinical trial cover.

Related Conditions & MeSH terms

• Heart Failure

Intervention

Device:
• Heartfelt device
The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark. The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless. In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition.

Locations

Country	Name	City	State
United Kingdom	Department of Cardiology, Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust (Blackpool Victoria Hospital), Whinney Heys Road.	Blackpool	Lancashire

Sponsors (2)

Lead Sponsor	Collaborator
Heartfelt Technologies	Blackpool Teaching Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Proportion of participants we can establish the number of days alive out of hospital in which the participant had significant weight gain	Proportion of participants for whom we can collect data using the study protocol to establish the number of days alive out of hospital in which the participant had a significant increase of weight (including both paper diary records and the provided Bluetooth scales).	60 days
Other	Proportion of participants we can establish the number of days alive out of hospital in which the device did not capture adequate images of the foot to generate a volume	Proportion of participants for whom we can safely collect data using the study protocol to establish the number of days alive out of hospital in which the Heartfelt device did not capture high enough quality images of the participant's foot to generate a volume.	60 days
Primary	Proportion of participants we can establish number of days alive out of hospital	The proportion of participants for whom we can collect data to establish the number of days alive and out of hospital.	60 days
Secondary	Proportion of participants we can establish number of days alive and well out of hospital	Proportion of participants for whom we can safely collect data using the study protocol to establish number of days alive out of hospital in which the participant reports feeling well.	60 days
Secondary	Proportion of participants who complete study questionnaires	Proportion of participants who complete the questionnaires to assess Mental Wellbeing Score, hopelessness, and satisfaction to service provided.	60 days
Secondary	True alerts - oedema	Proportion of "true alerts" corresponding to "increase in oedema".	60 days
Secondary	True alerts - diuretics	Proportion of "true alerts" corresponding to "increase in diuretics".	60 days
Secondary	Proportion of participants we can establish date of emergency hospital admission which is HF related	Proportion of participants for whom we can safely collect data using the study protocol to establish the date of emergency hospital admissions related to HF	60 days
Secondary	Proportion of participants we can establish date of emergency hospital admission due to any cause	Proportion of participants for whom we can safely collect data using the study protocol to establish the date of emergency hospital admission due to any cause.	60 days
Secondary	Proportion of participants we can establish date of planned hospital admission which is HF related	Proportion of participants for whom we can safely collect data using the study protocol to establish the date of planned hospital admissions related to HF	60 days
Secondary	Proportion of participants we can establish date of planned hospital admission due to any cause	Proportion of participants for whom we can safely collect data using the study protocol to establish the date of planned hospital admission due to any cause.	60 days
Secondary	Proportion of participants we can establish date of death	Proportion of participants in the study for whom the date of death can be established.	60 days
Secondary	Proportion of participants we can establish cause of death	Proportion of participants in the study for whom the cause of death can be established.	60 days
Secondary	Proportion of participants we can establish their quality of life	Proportion of participants for whom we can safely collect data using the study protocol to establish participant quality of life.	60 days
Secondary	Proportion of participants we can establish symptom reporting	Proportion of participants for whom we can safely collect data using the study protocol to establish symptom reporting.	60 days